GlassScriptPhysician profile
Max J Rabinowitz
NPI 1295770972
$13,912.33
in general payments reported to CMS, 2019-2025
86 companies · $3,042 in 2025
The $3,042 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,402 · 2020: $1,482 · 2021: $1,205 · 2022: $1,337 · 2023: $1,850 · 2024: $2,594 · 2025: $3,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,386 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,386.23 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,359.77 | 2019-2025 | Enhertu, Tagrisso, Calquence |
| Janssen Biotech, INC. | $870.92 | 2019-2025 | Rybrevant, Erleada, Balversa |
| Novartis Pharmaceuticals Corporation | $772.41 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $608.43 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Pfizer INC. | $561.75 | 2019-2025 | |
| Astellas Pharma US INC | $545.31 | 2019-2025 | Vyloy, Padcev, Xtandi |
| Celgene Corporation | $472.92 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Abbvie INC. | $415.17 | 2019-2025 | |
| Genentech USA, INC. | $399.96 | 2019-2025 | Polivy, Alecensa, Tecentriq |
| Amgen INC. | $345.89 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $335.88 | 2019-2023 | Imbruvica, Epkinly |
| Incyte Corporation | $311.89 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $303.75 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $276.01 | 2022-2025 | Libtayo |
| Seagen INC. | $275.86 | 2019-2023 | Tukysa, Adcetris, Padcev |
Show all 86 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Rabinowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.